Sign Up Today and Learn More About Zucara Therapeutics Stock
Invest in or calculate the value of your shares in Zucara Therapeutics or other pre-IPO companies through EquityZen's platform.
Zucara Therapeutics Stock (ZUTH)
Zucara Therapeutics is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in patients with diabetes.
About Zucara Therapeutics Stock
Founded
2015
Industries
Science and Engineering, Health Care, Biotechnology
Zucara Therapeutics Press Mentions
Stay in the know about the latest news on Zucara Therapeutics
Zucara Therapeutics: $25 Million Series B Closed For Diabetes Life Sciences Platform
pulse2 • May 04, 2025
Zucara Therapeutics Raises $5M in Second and Final Closing of US$25M Series B Financing
finsmes • May 02, 2025
Arvinas ends plans for two Phase 3 breast cancer trials; Phathom makes cuts
endpts • May 01, 2025
Zucara Therapeutics Announces Second and Final Closing of US$25 Million Series B Financing
morningstar • May 01, 2025
Zucara Therapeutics Announces Second and Final Closing of US$25 Million Series B Financing
prnewswire • May 01, 2025
Zucara Therapeutics Management
Leadership team at Zucara Therapeutics
Board Member
Michael Martin
CEO
Michael Midmer
Join now and verify your accreditation status to gain access to:
- Zucara Therapeutics Current Valuation
- Zucara Therapeutics Stock Price
- Zucara Therapeutics Management
- Available deals in Zucara Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Zucara Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Zucara Therapeutics Revenue and Financials
- Zucara Therapeutics Highlights
- Zucara Therapeutics Business Model
- Zucara Therapeutics Risk Factors
- Zucara Therapeutics Research Report from SACRA Research
Trading Zucara Therapeutics Stock
How to invest in Zucara Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Zucara Therapeutics through EquityZen funds. These investments are made available by existing Zucara Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Zucara Therapeutics stock?
Shareholders can sell their Zucara Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
